SGO 2022 Conference Coverage on VuMedi


 

SGO 2022 Final OS Results From SOLO3: Phase III Trial Assessing Olaparib Monotherapy vs. Non-Platinum Chemo in Heavily Pretreated Patients With Germline BRCA1 and/or BRCA2m Platinum-Sensitive Relapsed Ovarian Cancer

337 views
April 7, 2022
Comments 0
Login to view comments. Click here to Login